The drug was first approved in 2010 as a treatment for adults with schizophrenia, as well as adults experiencing major depressive episodes associated with bipolar I disorder.
Latuda is the first medication to be approved for adolescent patients with schizophrenia in five years, according to a news release.
More articles on supply chain:
Mylan CEO speaks out for 1st time since congressional hearing: 5 quotes
Target launches new guidelines to control chemicals in its supply chain
Shark antibodies could successfully transport drugs to brain
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
